ATRA stock icon

Atara Biotherapeutics
ATRA

$10.47
8.37%
 

About: Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Employees: 173

0
Funds holding %
of 6,702 funds
Analysts bullish %
0
News positive %
of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

74% more capital invested

Capital invested by funds: $33.2M [Q4 2023] → $57.9M (+$24.7M) [Q1 2024]

18.19% more ownership

Funds ownership: 63.52% [Q4 2023] → 81.71% (+18.19%) [Q1 2024]

4% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 28

11% less funds holding

Funds holding: 91 [Q4 2023] → 81 (-10) [Q1 2024]

15% less call options, than puts

Call options by funds: $33K | Put options by funds: $39K

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$58
449%
upside
Avg. target
$58
449%
upside
High target
$58
449%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Stifel
Benjamin Burnett
449%upside
$57.5
Hold
Maintained
1 Apr 2024

Financial journalist opinion

Based on 5 articles about ATRA published over the past 30 days